Nephrology

In our latest issue of EMJ Nephrology, discover the latest in the field, featuring developments in antibody-mediated rejection…

This article was funded by Sanofi and is intended for healthcare professionals.

We are delighted to share the latest issue of EMJ Nephrology with you, featuring peer-reviewed articles, as well as insightful interviews with esteemed experts in the field.

This infographic explores a contemporary strategy to decrease the risk of cardiovascular disease and mortality associated with end-stage kidney disease (ESKD).

This infographic explores the epidemiology, burden, and unmet need in IgA nephropathy (IgAN). Delving into the pathophysiology of IgAN, the infographic breaks down the different aspects of the kidney that are impacted by the inflammatory mediators endothelin-1 and angiotensin II.

Sharing key updates in the field in the form of reviews and research articles, our latest release features insights into COVID-19-associated nephropathy, diabetic kidney disease, and perspectives on the use of sodium-glucose co-transporter inhibitors in kidney disease.

In an interview conducted by EMJ, leading experts from the field of nephrology and renal medicine discussed the high mortality rates in patients on long-term haemodialysis (HD), despite the recent developments in treatment.

CHRONIC kidney disease (CKD) affects approximately 700 million individuals worldwide. Many patients with CKD require haemodialysis, and more than two-thirds of these patients have CKD-associated pruritus (CKD-aP). CKD-aP can be bothersome for many patients and drastically affect quality of life, from causing sleep issues to mental health problems. Almost 40% of dialysis patients are at least ‘moderately’ bothered and 19% of patients are at least very much bothered by pruritus.